Cycle Pharmaceuticals sole aim is to deliver best-in-class drug treatments and services to the under-served rare disease patient community. They focus on rare metabolic and neurological genetic disorders that require life-long treatment.
Cycle’s agreement with Deutsche Bank provides them with the capital to progress their innovative ideas and grow the business globally. The strategic financing allows cycle to build on their success of NITYR® which treats patients with the rare metabolic disease, hereditary tyrosinemia type-1.
BDO provided commercial due diligence support to Deutsche Bank.
“BDO's in-depth understanding of the pharma space allowed them to quickly and efficiently understand our business on behalf of the lender. They were able to focus on the most relevant value drivers in our business and carry out the work extremely effectively and were very easy to work with.”
James Harrison, Cycle Pharmaceuticals
Cycle Pharmaceuticals were featured as one of ten ‘Ones to Watch’ in the 2020 edition of The Sunday Times Tech Track 100 which ranks the UK’s fastest growing private technology, media, life sciences and telecoms companies.
BDO is proud to sponsor Tech Track and our teams are committed to celebrating and supporting high growth technology and life science businesses.
